Cambridge Quantum Computing (CQC) is pleased to announce their collaboration with Roche, to design and implement noisy-intermediate-scale-quantum (NISQ) algorithms for early-stage drug discovery and development.
The multi-year collaboration will combine the industry-leading expertise of both CQC and Roche to significantly advance the application of quantum computing to pharmaceutical relevant problems– accelerating the industry closer towards quantum advantage.
The collaboration will employ CQC’s leading quantum chemistry platform ‘EUMEN’, to augment the Alzheimer’s Disease research efforts of Roche. The collaboration will be recognised as one of the most substantive research efforts in the field of quantum computing to date, and strives to enable the development of next generation, quantum inspired therapeutics.
Ilyas Khan, CEO of CQC said, “For many years quantum computing has held out great promise for discovering new therapeutics that aid humanity in fighting some of the most devastating and damaging diseases. We are pleased that due to the careful and pioneering efforts of our research teams, some of this promise is starting to come to fruition. We are excited to collaborate with Roche and their quantum computing taskforce. It is a true privilege to collaborate in pursuit of quantum advantage.”
Founded in 2014 and backed by some of the world’s leading quantum computing companies, CQC is a global leader in quantum software and quantum algorithms, enabling clients to achieve the most out of rapidly evolving quantum computing hardware. CQC has offices in the UK, USA and Japan. For more information, visit CQC at http://www.cambridgequantum.com.